Metabolic Syndrome – Pipeline Review, H2 2013

75 pages report Published in
Pharmaceuticals
Publisher: Global Markets Direct

arrowFor This Report

Metabolic Syndrome – Pipeline Review, H2 2013

Summary

Global Markets Direct’s, ‘Metabolic Syndrome – Pipeline Review, H2 2013’, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Metabolic Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metabolic Syndrome. Metabolic Syndrome – Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– A snapshot of the global therapeutic scenario for Metabolic Syndrome.

– A review of the Metabolic Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

– Coverage of products based on various stages of development ranging from discovery till registration stages.

– A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

– Coverage of the Metabolic Syndrome pipeline on the basis of route of administration and molecule type.

– Key discontinued pipeline projects.

– Latest news and deals relating to the products.

Reasons to buy

– Identify and understand important and diverse types of therapeutics under development for Metabolic Syndrome.

– Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

– Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.

– Devise corrective measures for pipeline projects by understanding Metabolic Syndrome pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Metabolic Syndrome Overview 8

Therapeutics Development 9

An Overview of Pipeline Products for Metabolic Syndrome 9

Metabolic Syndrome Therapeutics under Development by Companies 11

Metabolic Syndrome Therapeutics under Investigation by Universities/Institutes 13

Late Stage Products 14

Comparative Analysis 14

Mid Clinical Stage Products 15

Comparative Analysis 15

Early Clinical Stage Products 16

Comparative Analysis 16

Discovery and Pre-Clinical Stage Products 17

Comparative Analysis 17

Metabolic Syndrome Therapeutics - Products under Development by Companies 18

Metabolic Syndrome Therapeutics - Products under Investigation by Universities/Institutes 19

Companies Involved in Metabolic Syndrome Therapeutics Development 20

Dainippon Sumitomo Pharma Co., Ltd. 20

HYUNDAI PHARM. CO., LTD. 21

Chipscreen Biosciences Ltd 22

Jenrin Discovery, Inc. 23

Phenex Pharmaceuticals AG 24

Abeille Pharmaceuticals, Inc. 25

Cortendo Invest AB 26

Spherix Incorporated 27

Ache Laboratorios Farmaceuticos S/A 28

Cardax Pharmaceuticals, Inc. 29

Ascenion GmbH 30

Metabolic Syndrome - Therapeutics Assessment 31

Assessment by Monotherapy Products 31

Assessment by Route of Administration 32

Assessment by Molecule Type 34

Drug Profiles 36

AB-3001 - Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

MBX-8025 - Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

CS-038 - Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

chloroquine - Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

CDX-085 - Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Drug Targeting Farnesoid X Receptor - Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

SPX-10624258 - Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Px-102 - Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

MB-12066 - Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

HOB-046 - Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

CDE-001 - Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

GQ-16 - Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Next Generation Cortisol Inhibitor - Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

ACH-09 - Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

ND-630 - Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

11 Beta Hydroxysteroid Dehydrogenase 1 Inhibitors - Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

MAS-G-Protein-Coupled Receptor Agonists - Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

KH-064 - Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

JD-5037 - Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

Metabolic Syndrome Program - Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

Metabolic Syndrome SIRT Program - Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

ZLN-005 - Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

Englerin A - Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Metabolic Syndrome Program - Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

Drug Targeting Fibroblast Activation Protein - Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

Px-103 - Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

Metabolic Syndrome Therapeutics - Drug Profile Updates 66

Metabolic Syndrome Therapeutics - Discontinued Products 68

Metabolic Syndrome Therapeutics - Dormant Products 69

Metabolic Syndrome - Product Development Milestones 70

Featured News & Press Releases 70

Aug 28, 2012: Cardax Pharma To Obtain Chinese Patent Protection For Lead Compound CDX-085 70

Apr 26, 2012: miRagen Announces Publication Of Data On MIRG-9103 In Journal Cell 70

Feb 27, 2012: Kadmon Announces Dosing Of First Patient In Phase I Study Of KD025 71

Sep 12, 2011: Cardiotrophin 1 Shows Promising Results For Treatment Of Obesity And Metabolic Syndrome 72

Jun 07, 2008: Orexigen Therapeutics Announces That Contrave May Reverse The Incidence Of Metabolic Syndrome 72

Appendix 74

Methodology 74

Coverage 74

Secondary Research 74

Primary Research 74

Expert Panel Validation 74

Contact Us 75

Disclaimer 75



List of Tables

Number of Products Under Development for Metabolic Syndrome, H2 2013 9

Products under Development for Metabolic Syndrome - Comparative Analysis, H2 2013 10

Number of Products under Development by Companies, H2 2013 12

Number of Products under Investigation by Universities/Institutes, H2 2013 13

Comparative Analysis by Late Stage Development, H2 2013 14

Comparative Analysis by Mid Clinical Stage Development, H2 2013 15

Comparative Analysis by Early Clinical Stage Development, H2 2013 16

Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 17

Products under Development by Companies, H2 2013 18

Products under Investigation by Universities/Institutes, H2 2013 19

Dainippon Sumitomo Pharma Co., Ltd., H2 2013 20

HYUNDAI PHARM. CO., LTD., H2 2013 21

Chipscreen Biosciences Ltd, H2 2013 22

Jenrin Discovery, Inc., H2 2013 23

Phenex Pharmaceuticals AG, H2 2013 24

Abeille Pharmaceuticals, Inc., H2 2013 25

Cortendo Invest AB, H2 2013 26

Spherix Incorporated, H2 2013 27

Ache Laboratorios Farmaceuticos S/A, H2 2013 28

Cardax Pharmaceuticals, Inc., H2 2013 29

Ascenion GmbH, H2 2013 30

Assessment by Monotherapy Products, H2 2013 31

Assessment by Stage and Route of Administration, H2 2013 33

Assessment by Stage and Molecule Type, H2 2013 35

Metabolic Syndrome Therapeutics - Drug Profile Updates 66

Metabolic Syndrome Therapeutics - Discontinued Products 68

Metabolic Syndrome Therapeutics - Dormant Products 69



List of Figures

Number of Products under Development for Metabolic Syndrome, H2 2013 9

Products under Development for Metabolic Syndrome - Comparative Analysis, H2 2013 10

Products under Development by Companies, H2 2013 11

Products under Investigation by Universities/Institutes, H2 2013 13

Late Stage Products, H2 2013 14

Mid Clinical Stage Products, H2 2013 15

Early Clinical Stage Products, H2 2013 16

Discovery and Pre-Clinical Stage Products, H2 2013 17

Assessment by Monotherapy Products, H2 2013 31

Assessment by Route of Administration, H2 2013 32

Assessment by Stage and Route of Administration, H2 2013 33

Assessment by Molecule Type, H2 2013 34

Assessment by Stage and Molecule Type, H2 2013 35

Related Reports

  • Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) – Pipeline Review, H2 2014Global Markets Direct's, ‘Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Pipeline Review, H2 2014', provides an overview of the Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action […]
  • Prader-Willi Syndrome (PWS) – Pipeline Review, H2 2014Global Markets Direct's, ‘Prader-Willi Syndrome (PWS) - Pipeline Review, H2 2014', provides an overview of the Prader-Willi Syndrome (PWS)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Prader-Willi Syndrome (PWS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured […]
  • Neuromyelitis Optica (Devic’s Syndrome) – Pipeline Review, H2 2014Global Markets Direct's, ‘Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2014', provides an overview of the Neuromyelitis Optica (Devic's Syndrome)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Neuromyelitis Optica (Devic's Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along […]
  • Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) – Pipeline Review, H2 2014Global Markets Direct's, ‘Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H2 2014', provides an overview of the Metastatic Transitional Cell Cancer (Urothelial Cell Cancer)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Metastatic Transitional Cell Cancer (Urothelial Cell Cancer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of […]
  • Head And Neck Cancer – Pipeline Review, H1 2015Global Markets Direct's, ‘Head And Neck Cancer - Pipeline Review, H1 2015', provides an overview of the Head And Neck Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press […]